No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Hägglund
H
H
Division of Transplant Surgery, Huddinge Hospital, Sweden.
Ringdén
O
O
Ljungman
P
P
Winiarski
J
J
Ericzon
B
B
Tydén
G
G
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000209:etiology* / Q000601:surgery; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*; D014184:Transplantation, Homologous
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator